Friday, 14 Feb 2020

You are here

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.

A total of 36 TAK patients were enrolled in a randomized, double-blind, placebo-controlled study (TAKT - Takayasu arteritis Treated with Tocilizumab). after which they were given open-label, weekly s.c. tocilizumab 162 mg for up to 96 weeks or longer.  Glucocorticoid tapering was performed at the investigators’ discretion.

A total of 28 patients received open-label tocilizumab for 96 weeks.

The median glucocorticoid dose was 0.223 mg/kg/day at study entry; 0.131 mg/kg/day after 48 weeks; and 0.105 mg/kg/day after 96 weeks.

Overall, 46.4% of patients reduced their dose to <0.1 mg/kg/day, which was less than half the dose administered at relapse before study entry

Using imaging studies patients’ disease either was improved (17.9%) or stable (67.9%) after 96 weeks.

No unexpected safety issues were reported.

These results provide evidence of a steroid-sparing effect when TCZ is used in Takayasu arteritis patients.
 
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

PEXIVAS - Plasma Exhange Fails to Boost Outcomes in Severe AAV

The PEXIVAS study showed that plasma exchange did not reduce the incidence of death or ESKD in patients with severe ANCA–associated vasculitis.

Shingles Vaccine Lowers Risk of CVA

Shingles infection has been historically linked to an increased risk of stroke. A new study found that Zoster Vaccine Live, one type of shingles vaccination, may prevent stroke in some older adults.

EULAR Recommendations on Sjögren’s Syndrome

The European League Against Rheumatism (EULAR) has established an international collaborative group (EULAR SS Task Force) to develop the first EULAR evidence and consensus-based recommendations for the management of patients with Sjogens syndrome (SjS).

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.